159 related articles for article (PubMed ID: 33799050)
1. Oxycodone findings and CYP2D6 function in postmortem cases.
Jakobsson G; Larsson R; Pellè L; Kronstrand R; Gréen H
Forensic Sci Int Genet; 2021 Jul; 53():102510. PubMed ID: 33799050
[TBL] [Abstract][Full Text] [Related]
2. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.
Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
Br J Pharmacol; 2010 Jun; 160(4):907-18. PubMed ID: 20590587
[TBL] [Abstract][Full Text] [Related]
3. CYP2D6 genotype dependent oxycodone metabolism in postoperative patients.
Stamer UM; Zhang L; Book M; Lehmann LE; Stuber F; Musshoff F
PLoS One; 2013; 8(3):e60239. PubMed ID: 23555934
[TBL] [Abstract][Full Text] [Related]
4. CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients.
Balyan R; Mecoli M; Venkatasubramanian R; Chidambaran V; Kamos N; Clay S; Moore DL; Mavi J; Glover CD; Szmuk P; Vinks A; Sadhasivam S
Pharmacogenomics; 2017 Mar; 18(4):337-348. PubMed ID: 28244808
[TBL] [Abstract][Full Text] [Related]
5. Cancer cachexia raises the plasma concentration of oxymorphone through the reduction of CYP3A but not CYP2D6 in oxycodone-treated patients.
Naito T; Tashiro M; Ishida T; Ohnishi K; Kawakami J
J Clin Pharmacol; 2013 Aug; 53(8):812-8. PubMed ID: 23733622
[TBL] [Abstract][Full Text] [Related]
6. Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia.
Zwisler ST; Enggaard TP; Mikkelsen S; Brosen K; Sindrup SH
Acta Anaesthesiol Scand; 2010 Feb; 54(2):232-40. PubMed ID: 19719813
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.
Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
Br J Pharmacol; 2010 Jun; 160(4):919-30. PubMed ID: 20590588
[TBL] [Abstract][Full Text] [Related]
8. Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups.
Liukas A; Kuusniemi K; Aantaa R; Virolainen P; Neuvonen M; Neuvonen PJ; Olkkola KT
Drugs Aging; 2011 Jan; 28(1):41-50. PubMed ID: 21174486
[TBL] [Abstract][Full Text] [Related]
9. Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study.
Andreassen TN; Eftedal I; Klepstad P; Davies A; Bjordal K; Lundström S; Kaasa S; Dale O
Eur J Clin Pharmacol; 2012 Jan; 68(1):55-64. PubMed ID: 21735164
[TBL] [Abstract][Full Text] [Related]
10. Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness.
Linares OA; Daly D; Linares AD; Stefanovski D; Boston RC
Pain Med; 2014 May; 15(5):791-806. PubMed ID: 24517173
[TBL] [Abstract][Full Text] [Related]
11. CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone.
Naito T; Takashina Y; Yamamoto K; Tashiro M; Ohnishi K; Kagawa Y; Kawakami J
J Clin Pharmacol; 2011 Nov; 51(11):1529-38. PubMed ID: 21209234
[TBL] [Abstract][Full Text] [Related]
12. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.
Heiskanen T; Olkkola KT; Kalso E
Clin Pharmacol Ther; 1998 Dec; 64(6):603-11. PubMed ID: 9871425
[TBL] [Abstract][Full Text] [Related]
13. Determination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applications.
Fang WB; Lofwall MR; Walsh SL; Moody DE
J Anal Toxicol; 2013; 37(6):337-44. PubMed ID: 23743505
[TBL] [Abstract][Full Text] [Related]
14. Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.
Kummer O; Hammann F; Moser C; Schaller O; Drewe J; Krähenbühl S
Eur J Clin Pharmacol; 2011 Jan; 67(1):63-71. PubMed ID: 20857093
[TBL] [Abstract][Full Text] [Related]
15. Observations of urinary oxycodone and metabolite distributions in pain patients.
Elder NM; Atayee RS; Best BM; Ma JD
J Anal Toxicol; 2014 Apr; 38(3):129-34. PubMed ID: 24523296
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetic aspects of tramadol pharmacokinetics and pharmacodynamics after a single oral dose.
Bastami S; Haage P; Kronstrand R; Kugelberg FC; Zackrisson AL; Uppugunduri S
Forensic Sci Int; 2014 May; 238():125-32. PubMed ID: 24709712
[TBL] [Abstract][Full Text] [Related]
17. The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism.
Zwisler ST; Enggaard TP; Noehr-Jensen L; Pedersen RS; Mikkelsen S; Nielsen F; Brosen K; Sindrup SH
Basic Clin Pharmacol Toxicol; 2009 Apr; 104(4):335-44. PubMed ID: 19281600
[TBL] [Abstract][Full Text] [Related]
18. A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine.
Jornil J; Nielsen TS; Rosendal I; Ahlner J; Zackrisson AL; Boel LW; Brock B
Forensic Sci Int; 2013 Mar; 226(1-3):e26-31. PubMed ID: 23332809
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomics as molecular autopsy for postmortem forensic toxicology: genotyping cytochrome P450 2D6 for oxycodone cases.
Jannetto PJ; Wong SH; Gock SB; Laleli-Sahin E; Schur BC; Jentzen JM
J Anal Toxicol; 2002 Oct; 26(7):438-47. PubMed ID: 12422998
[TBL] [Abstract][Full Text] [Related]
20. Determination of oxycodone, noroxycodone, oxymorphone, and noroxymorphone in human plasma by liquid chromatography-electrospray-tandem mass spectrometry.
Neuvonen M; Neuvonen PJ
Ther Drug Monit; 2008 Jun; 30(3):333-40. PubMed ID: 18520605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
